タイプライター・セラピューティクス、RAキャピタル・マネジメントとANベンチャーズをリードとする投資家から500万ドルを資金調達 Typewriter Therapeutics Feb 27, 2024 12:00 JST Read More
Eisai to Boost Initiatives on Greenhouse Gas Reduction, Aiming to Achieve Net Zero by 2050 Eisai Feb 21, 2024 14:26 HKT/SGT Read More
Eisai Selected for 'Human Capital Leaders 2023' and 'Human Capital Management Gold Quality', Recognized as Company Committed to Excellent Management and Disclosure of Human Capital Initiatives Eisai Feb 20, 2024 08:35 HKT/SGT Read More
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Approved in Japan Eisai Feb 16, 2024 08:31 HKT/SGT Read More
BioAdaptives' Subsidiary, Livestock Impact, Inc. Celebrates Banner 2023 Equine Championship Titles Attributed to Its Advanced Proprietary Supplement Products BioAdaptives, Inc. Feb 01, 2024 04:00 HKT/SGT Read More
Eisai Submits New Drug Application for Mecobalamin Ultrahigh-Dose Formulation in Japan for the Indication of Amyotrophic Lateral Sclerosis Eisai Jan 26, 2024 15:26 HKT/SGT Read More
Olympus Closes the Acquisition of Korean Gastrointestinal Stent Company, Taewoong Medical Co., Ltd Olympus Jan 24, 2024 14:00 HKT/SGT Read More
Eisai: Antiepileptic Drug Fycompa Injection Formulation Approved in Japan Eisai Jan 18, 2024 14:12 HKT/SGT Read More
Eisai Listed as a Global 100 Most Sustainable Corporation for the Eighth Time Eisai Jan 17, 2024 16:08 HKT/SGT Read More
Eisai Furthers Oncology Research Across Multiple Cancers at ASCO GI and ASCO GU 2024 Eisai Jan 16, 2024 09:25 HKT/SGT Read More
Eisai: The Scientific Advisory Group (SAG) to Convene to Discuss the Marketing Authorization Application for lecanemab in the EU Eisai Jan 11, 2024 15:33 HKT/SGT Read More
Eisai: "LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in China Eisai Jan 10, 2024 09:15 HKT/SGT Read More
Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050 NEC Corporation Jan 09, 2024 15:30 HKT/SGT Read More
Development of Prediction Model for Brain Amyloid-Beta Accumulation Using Wristband Sensor Eisai Dec 29, 2023 13:30 HKT/SGT Read More
Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Tasurgratinib for Biliary Tract Cancer with Fgfr2 Gene Fusion Eisai Dec 19, 2023 16:24 HKT/SGT Read More
Eisai and Mizuho Sign Sustainability-Linked Loan Agreement Eisai Dec 14, 2023 17:02 HKT/SGT Read More
